Onassis Holdings Retained Investment Bank Dalmore Group to Launch up to $75 Million Regulation A+ Offering (Mini IPO)

Onassis Holdings Corp (OTC: ONSS), a biotech holding company specializing in longevity and rejuvenation technologies, has announced its decision to raise up to $75 million through a Regulation A+ financing round. This initiative follows a strategic partnership with Dalmore Group, an investment bank known for its expertise in capital raising via Regulation A+, CF, and D offerings. Since its inception, Dalmore Group has successfully assisted over 270 Reg A+ issuers, raising more than $2 billion, and processed over a million investor transactions.

Regulation A+ allows companies like Onassis to attract investments from both accredited and non-accredited investors, streamlining the fundraising process compared to traditional public offerings. This capital will be pivotal for Onassis as it aims to continue developing advanced therapies aimed at rejuvenating aging cells while preserving their unique properties, primarily through their subsidiary, Ananda Labs Inc.

The collaboration with Dalmore is expected to enhance Onassis’ visibility and accessibility in the investment community through expert marketing, public relations, and syndication arrangements. Furthermore, Dalmore’s extensive experience and established relationships in diverse financial markets position it as a key ally in navigating the complexities of Reg A+ offerings.

It is important to note that any projections or statements regarding future performance made in the announcement are classified as "forward-looking statements." These statements are subject to risks and uncertainties that could lead to outcomes differing from current expectations.

For more details, interested parties can visit Onassis Holdings’ website or contact them directly.

Onassis Holdings Corp (OTC: ONSS) is actively seeking to raise up to $75 million through a Regulation A+ offering, in partnership with Dalmore Group, a proficient investment bank with a robust track record in capital raises. This initiative marks a significant milestone for Onassis, a biotech firm dedicated to longevity and rejuvenation technologies, particularly through its subsidiary Ananda Labs.

Investors should be mindful that the Regulation A+ framework facilitates companies to gain access to public capital with a streamlined approach, as it allows offerings to a broader base of investors, including non-accredited individuals. The backing of Dalmore Group, which has successfully helped onboard over 270 Regulation A+ issuers and has raised more than $2 billion, bodes well for the potential success of this offering.

An additional point of caution for investors is the nature of the biotech sector, known for its volatility and high susceptibility to regulatory scrutiny and clinical trial outcomes. Onassis' focus on epigenetics and patented therapies creates a promising avenue, but such endeavors traditionally carry higher risks, and successful commercialization is often uncertain.

While the potential for high returns exists if Ananda Labs can effectively bring its innovative therapy to market, investors should carefully consider their risk tolerance and the inherent uncertainties of biopharmaceutical development. Furthermore, Onassis’ ability to leverage Dalmore’s expertise in marketing, syndication, and secondary trading increases the likelihood of reaching its funding goals, enhancing visibility and credence in the eyes of potential investors.

Investors interested in this mini IPO should pursue due diligence, keeping a close watch on future developments and partnerships. Understanding both the bullish prospects and the underlying risks associated with biotech investments will be critical for making informed decisions surrounding Onassis Holdings.